292 related articles for article (PubMed ID: 27999208)
41. Diagnostic value of RASSF1A methylation for breast cancer: a meta-analysis.
Li M; Wang C; Yu B; Zhang X; Shi F; Liu X
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31196964
[TBL] [Abstract][Full Text] [Related]
42. Promoter methylation and gene polymorphism are two independent events in regulation of GSTP1 gene expression.
Bhat A; Masood A; Wani KA; Bhat YA; Nissar B; Khan NS; Ganai BA
Tumour Biol; 2017 Apr; 39(4):1010428317697563. PubMed ID: 28443466
[TBL] [Abstract][Full Text] [Related]
43. Value of circulating cell-free DNA analysis as a diagnostic tool for breast cancer: a meta-analysis.
Lin Z; Neiswender J; Fang B; Ma X; Zhang J; Hu X
Oncotarget; 2017 Apr; 8(16):26625-26636. PubMed ID: 28460452
[TBL] [Abstract][Full Text] [Related]
44. Sox17 promoter methylation in plasma DNA is associated with poor survival and can be used as a prognostic factor in breast cancer.
Fu D; Ren C; Tan H; Wei J; Zhu Y; He C; Shao W; Zhang J
Medicine (Baltimore); 2015 Mar; 94(11):e637. PubMed ID: 25789956
[TBL] [Abstract][Full Text] [Related]
45. PTPH1 immunohistochemical expression and promoter methylation in breast cancer patients from India: A retrospective study.
Venkatesh T; Shetty A; Chakraborti S; Suresh PS
J Cell Physiol; 2019 Feb; 234(2):1071-1079. PubMed ID: 30189107
[TBL] [Abstract][Full Text] [Related]
46. Methylation Analysis of BRCA1 and APC in Breast Cancer and It's Relationship to Clinicopathological Features.
Shakeri H; Fakhrjou A; Nikanfar A; Mohaddes-Ardebili SM
Clin Lab; 2016 Dec; 62(12):2333-2337. PubMed ID: 28164568
[TBL] [Abstract][Full Text] [Related]
47. DNA promoter hypermethylation profiles in breast duct fluid.
Twelves D; Nerurkar A; Osin P; Dexter T; Ward A; Gui GP; Isacke CM
Breast Cancer Res Treat; 2013 Jun; 139(2):341-50. PubMed ID: 23674191
[TBL] [Abstract][Full Text] [Related]
48. Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARβ2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay.
Yamamoto N; Nakayama T; Kajita M; Miyake T; Iwamoto T; Kim SJ; Sakai A; Ishihara H; Tamaki Y; Noguchi S
Breast Cancer Res Treat; 2012 Feb; 132(1):165-73. PubMed ID: 21594664
[TBL] [Abstract][Full Text] [Related]
49. Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancer.
Spitzwieser M; Holzweber E; Pfeiler G; Hacker S; Cichna-Markl M
Breast Cancer Res; 2015 Sep; 17(1):125. PubMed ID: 26370119
[TBL] [Abstract][Full Text] [Related]
50. Zic1 Promoter Hypermethylation in Plasma DNA Is a Potential Biomarker for Gastric Cancer and Intraepithelial Neoplasia.
Chen X; Lin Z; Xue M; Si J; Chen S
PLoS One; 2015; 10(7):e0133906. PubMed ID: 26207911
[TBL] [Abstract][Full Text] [Related]
51. Intermediate filament dynamics and breast cancer: aberrant promoter methylation of the Synemin gene is associated with early tumor relapse.
Noetzel E; Rose M; Sevinc E; Hilgers RD; Hartmann A; Naami A; Knüchel R; Dahl E
Oncogene; 2010 Aug; 29(34):4814-25. PubMed ID: 20543860
[TBL] [Abstract][Full Text] [Related]
52. Clinicopathological Significance and Diagnostic Value of DLEC1 Hypermethylation in Lung Cancer: A Meta-analysis.
Li X; Mao W; Guo D; Xu H
J Nippon Med Sch; 2019; 86(2):62-69. PubMed ID: 31130567
[TBL] [Abstract][Full Text] [Related]
53. Pathological complete response of HER2-positive breast cancer to trastuzumab and chemotherapy can be predicted by HSD17B4 methylation.
Fujii S; Yamashita S; Yamaguchi T; Takahashi M; Hozumi Y; Ushijima T; Mukai H
Oncotarget; 2017 Mar; 8(12):19039-19048. PubMed ID: 28186977
[TBL] [Abstract][Full Text] [Related]
54. Cell-free DNA promoter hypermethylation in plasma as a diagnostic marker for pancreatic adenocarcinoma.
Henriksen SD; Madsen PH; Larsen AC; Johansen MB; Drewes AM; Pedersen IS; Krarup H; Thorlacius-Ussing O
Clin Epigenetics; 2016; 8():117. PubMed ID: 27891190
[TBL] [Abstract][Full Text] [Related]
55. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.
Jiang Y; Tong D; Lou G; Zhang Y; Geng J
Pathobiology; 2008; 75(4):244-51. PubMed ID: 18580070
[TBL] [Abstract][Full Text] [Related]
56. Breast cancer metastasis suppressor-1 promoter methylation in primary breast tumors and corresponding circulating tumor cells.
Chimonidou M; Kallergi G; Georgoulias V; Welch DR; Lianidou ES
Mol Cancer Res; 2013 Oct; 11(10):1248-57. PubMed ID: 23744981
[TBL] [Abstract][Full Text] [Related]
57. Aberrantly Methylated cfDNA in Body Fluids as a Promising Diagnostic Tool for Early Detection of Breast Cancer.
Stastny I; Zubor P; Kajo K; Kubatka P; Golubnitschaja O; Dankova Z
Clin Breast Cancer; 2020 Dec; 20(6):e711-e722. PubMed ID: 32792225
[TBL] [Abstract][Full Text] [Related]
58. The novel TP53 3'-end methylation pattern associated with its expression would be a potential biomarker for breast cancer detection.
Zeng F; Heng J; Guo X; Wang Y; Wu W; Tang L; Chen M; Wang S; Deng H; Wang J
Breast Cancer Res Treat; 2020 Feb; 180(1):237-245. PubMed ID: 31983017
[TBL] [Abstract][Full Text] [Related]
59. Promoter methylation status of the FHIT gene and Fhit expression: association with HER2/neu status in breast cancer patients.
Jeong YJ; Jeong HY; Lee SM; Bong JG; Park SH; Oh HK
Oncol Rep; 2013 Nov; 30(5):2270-8. PubMed ID: 23969757
[TBL] [Abstract][Full Text] [Related]
60. Probing of breast cancer using a combination of plasma and urinary circulating cell-free DNA.
Zuo Z; Tang J; Cai X; Ke F; Shi Z
Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33044511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
